Early use of vedolizumab vs. infliximab in biologic-naive patients with ulcerative colitis: A real-world analysis of healthcare utilisation

被引：0
|
作者：
Patel, H. [1 ]
Khalid, J. M. [1 ]
Shah, S. [2 ]
Shah, R. [3 ]
Berger, A. [2 ]
机构：
[1] Takeda Dev Ctr Europe Ltd, Evidence & Value Generat, London, England
[2] Evidera, Real World Evidence, Waltham, MA USA
[3] Evidera, Real World Evidence, London, England
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P552
引用
收藏
页码：S385 / S386
页数：2
相关论文
共 50 条
  • [21] REAL-WORLD EXPERIENCE OF USING TOFACITINIB IN ULCERATIVE COLITIS IN BIOLOGIC NAIVE AND BIOLOGIC EXPOSED PATIENTS
    Cheesbrough, Jonathan
    Sharma, Naveen
    Nassar, Islam
    Quraishi, Nabil
    GUT, 2022, 71 : A42 - A42
  • [22] Real-world experience of using Tofacitinib in Ulcerative Colitis in biologic naive and biologic exposed patients
    Cheesbrough, J.
    Quraishi, M. N.
    Sharma, N.
    Nassar, I.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I443 - I444
  • [23] Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naive vs. non-naive patients
    van Lumig, P. P. M.
    van de Kerkhof, P. C. M.
    Boezeman, J. B. M.
    Driessen, R. J. B.
    de Jong, E. M. G. J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (05) : 593 - 600
  • [24] Hospitalisations, Flares, and Corticosteroid Use Outcomes in Biologic-Naive Patients with Ulcerative Colitis and Crohn's Disease Initiating Vedolizumab
    Alam, Naufil
    Raluy-Callado, Mireia
    Donaldson, Robert
    Kaviya, Arpeat
    Khalid, Javaria
    INFLAMMATORY BOWEL DISEASES, 2017, 23 : S26 - S27
  • [25] COMPARATIVE EFFECTIVENESS OF VEDOLIZUMAB VS. INFLIXIMAB INDUCTION THERAPY IN ULCERATIVE COLITIS: EXPERIENCE OF A REAL-WORLD COHORT AT A TERTIARY IBD CENTER
    Allamneni, Chaitanya
    Venkata, Krishna
    Xie, Fenglong
    DeLoach, Lindsey
    Malik, Talha
    GASTROENTEROLOGY, 2018, 154 (01) : S72 - S72
  • [26] COMPARATIVE EFFECTIVENESS OF VEDOLIZUMAB VS. INFLIXIMAB INDUCTION THERAPY IN ULCERATIVE COLITIS: EXPERIENCE OF A REAL-WORLD COHORT AT A TERTIARY IBD CENTER
    Allamneni, Chaitanya
    Venkata, Krishna
    Xie, Fenglong
    DeLoach, Lindsey
    Malik, Talha
    INFLAMMATORY BOWEL DISEASES, 2018, 24 : S49 - S50
  • [27] Comparison of long-term outcomes of infliximab and adalimumab in biologic-naive patients with ulcerative colitis
    Durak, M. B.
    Baspinar, B.
    Guven, I. E.
    Kivrakoglu, F.
    Kilic, V.
    Kosar, K.
    Erdogan, C.
    Yuksel, I.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I547 - I547
  • [28] Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study
    Singh, Siddharth
    Andersen, Nynne Nyboe
    Andersson, Mikael
    Loftus, Edward V., Jr.
    Jess, Tine
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2017, 15 (08) : 1218 - +
  • [29] Comparison of long-term outcomes of infliximab and adalimumab in biologic-naive patients with ulcerative colitis
    Durak, M. B.
    Baspinar, B.
    Guven, I. E.
    Kivrakoglu, F.
    Kilic, V.
    Kosar, K.
    Erdogan, C.
    Yuksel, I.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I547 - I547
  • [30] Comparative Risk of Clostridioides Difficile Infection in Vedolizumab vs anti-TNFa Agents in Biologic-Naive Patients With Ulcerative Colitis
    Rahul, Dalal
    Jennifer, Mitri
    Hannah, Goodrick
    Jessica, Allegretti
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S19 - S19
12345